70 related articles for article (PubMed ID: 3301710)
1. Femoxetine in the treatment of obese patients in general practice. A randomized group comparative study with placebo.
Bitsch M; Skrumsager BK
Int J Obes; 1987; 11(2):183-90. PubMed ID: 3301710
[TBL] [Abstract][Full Text] [Related]
2. Femoxetine and amitriptyline in general practice: a randomized double-blind group comparison.
Skrumsager BK; Jeppesen K
Pharmacopsychiatry; 1986 Sep; 19(5):368-77. PubMed ID: 3774871
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerance of femoxetine and imipramine in the treatment of depressive states. A randomized, double-blind study.
Suominen J; Tamminen T; Elosuo R; Manniche PM
Pharmacopsychiatry; 1988 Sep; 21(5):238-44. PubMed ID: 3067246
[TBL] [Abstract][Full Text] [Related]
4. Femoxetine in the prophylaxis of migraine--a randomised comparison with placebo.
Zeeberg I; Orholm M; Nielsen JD; Honore PL; Larsen JJ
Acta Neurol Scand; 1981 Dec; 64(6):452-9. PubMed ID: 6753446
[TBL] [Abstract][Full Text] [Related]
5. A controlled double-blind study of femoxetine and amitriptyline in patients with endogenous depression.
Reebye PN; Yiptong C; Samsoon J; Schulsinger F; Fabricius J
Pharmacopsychiatria; 1982 Sep; 15(5):164-9. PubMed ID: 6757983
[TBL] [Abstract][Full Text] [Related]
6. [Treatment of obesity in general practice with femoxetine. A controlled clinical trial of the effects of femoxetine and placebo].
Kristensen JS; Christiansen P; Skrumsager BK
Ugeskr Laeger; 1982 Mar; 144(13):939-42. PubMed ID: 7048680
[No Abstract] [Full Text] [Related]
7. The treatment of accessory symptoms in narcolepsy: a double-blind cross-over study of a selective serotonin re-uptake inhibitor (femoxetine) versus placebo.
Schrader H; Kayed K; Bendixen Markset AC; Treidene HE
Acta Neurol Scand; 1986 Oct; 74(4):297-303. PubMed ID: 3544654
[TBL] [Abstract][Full Text] [Related]
8. A comparative study of phentermine and diethylpropion in the treatment of obese patients in general practice.
Vallé-Jones JC; Brodie NH; O'Hara H; O'Hara J; McGhie RL
Pharmatherapeutica; 1983; 3(5):300-4. PubMed ID: 6844367
[TBL] [Abstract][Full Text] [Related]
9. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study.
Muls E; Kolanowski J; Scheen A; Van Gaal L;
Int J Obes Relat Metab Disord; 2001 Nov; 25(11):1713-21. PubMed ID: 11753595
[TBL] [Abstract][Full Text] [Related]
10. So-called "tension headache"--the response to a 5-HT uptake inhibitor: femoxetine.
Sjaastad O
Cephalalgia; 1983 Mar; 3(1):53-60. PubMed ID: 6850822
[TBL] [Abstract][Full Text] [Related]
11. Long-term maintenance of weight loss with sibutramine in a GP setting following a specialist guided very-low-calorie diet: a double-blind, placebo-controlled, parallel group study.
Mathus-Vliegen EM;
Eur J Clin Nutr; 2005 Aug; 59 Suppl 1():S31-8; discussion S39. PubMed ID: 16052193
[TBL] [Abstract][Full Text] [Related]
12. A randomized general practice group-comparative study of femoxetine and placebo in the prophylaxis of migraine.
Orholm M; Honoré PF; Zeeberg I
Acta Neurol Scand; 1986 Sep; 74(3):235-9. PubMed ID: 3538753
[TBL] [Abstract][Full Text] [Related]
13. Does ephedrine promote weight loss in low-energy-adapted obese women?
Pasquali R; Cesari MP; Melchionda N; Stefanini C; Raitano A; Labo G
Int J Obes; 1987; 11(2):163-8. PubMed ID: 3301709
[TBL] [Abstract][Full Text] [Related]
14. Cardiovascular (ECG and systolic time intervals) and anticholinergic effects of repeated doses of femoxetine--a comparison with amitriptyline and placebo in healthy men.
Warrington SJ; Turner P; Skrumsager BK
Br J Clin Pharmacol; 1989 Mar; 27(3):343-51. PubMed ID: 2719894
[TBL] [Abstract][Full Text] [Related]
15. A dietary fibre supplement and weight maintenance after weight reduction: a randomized, double-blind, placebo-controlled long-term trial.
Ryttig KR; Tellnes G; Haegh L; Bøe E; Fagerthun H
Int J Obes; 1989; 13(2):165-71. PubMed ID: 2545640
[TBL] [Abstract][Full Text] [Related]
16. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms.
Jain AK; Kaplan RA; Gadde KM; Wadden TA; Allison DB; Brewer ER; Leadbetter RA; Richard N; Haight B; Jamerson BD; Buaron KS; Metz A
Obes Res; 2002 Oct; 10(10):1049-56. PubMed ID: 12376586
[TBL] [Abstract][Full Text] [Related]
17. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
[TBL] [Abstract][Full Text] [Related]
18. "Treatment of obesity by femoxetine a selective 5 HT reuptake inhibitor'.
Smedegaard J; Christiansen P; Skrumsager B
Int J Obes; 1981; 5(4):377-8. PubMed ID: 7309322
[No Abstract] [Full Text] [Related]
19. Dexfenfluramine as adjuvant to a low-calorie formula diet in the treatment of obesity: a randomized clinical trial.
Andersen T; Astrup A; Quaade F
Int J Obes Relat Metab Disord; 1992 Jan; 16(1):35-40. PubMed ID: 1314242
[TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.
Wilding J; Van Gaal L; Rissanen A; Vercruysse F; Fitchet M;
Int J Obes Relat Metab Disord; 2004 Nov; 28(11):1399-410. PubMed ID: 15486569
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
